Lead Excretion Promotion Function Test: Principles, Methods, and Evaluation Criteria

The Lead Excretion Promotion Function Test is a standardized biological evaluation used to verify whether health food products can effectively accelerate the elimination of lead from the body. This test combines animal experiments and human feeding trials to measure lead levels in blood, bone, urine, and feces, providing scientific evidence required for functional claim substantiation and regulatory registration of lead-excreting health products. This article presents a comprehensive technical overview of the testing principles, sample requirements, analytical items, methods, and application scenarios.

Technical Overview

Lead is a cumulative toxic heavy metal that enters the human body mainly through ingestion and inhalation, and it is stored predominantly in bone tissue, where it accounts for more than 90 percent of the total body lead burden. Because lead is excreted slowly and can cause damage to the nervous, hematopoietic, digestive, and renal systems, functional foods that promote lead excretion have become an important category in the health food industry. The Lead Excretion Promotion Function Test is designed to evaluate whether a test substance can accelerate the elimination of lead from lead-loaded organisms and reduce the lead burden in critical tissues.

The evaluation is typically performed in accordance with the Technical Standards for Testing and Assessment of Health Food (GB 15193 series for supporting toxicological work) and the health food function evaluation procedures published by the national health administration. The core scientific rationale is to establish a lead-burdened animal model using lead acetate administration, treat the model animals with the test substance at multiple dose levels, and then quantify lead concentrations in blood, bone, liver, kidney, urine, and feces. A positive result is achieved when the test substance significantly reduces tissue lead levels or significantly increases urinary and fecal lead excretion compared with the lead-loaded control group, without producing adverse effects or depleting essential trace elements.

For products intended to carry a functional claim, a human feeding trial must also be conducted in adult volunteers with elevated blood lead levels to confirm efficacy and safety in the target population. The complete test battery demonstrates both the functional mechanism and the practical benefit of the product under real-world exposure conditions.

Testing Samples

Health Food Products

Finished health food products in various dosage forms, including tablets, capsules, softgels, oral liquids, granules, powders, and functional beverages, can be submitted for evaluation. Samples must be representative of the final commercial formulation, with the active ingredients, excipients, and recommended daily intake clearly documented.

Functional Ingredients and Raw Materials

Individual functional ingredients or novel food raw materials with potential lead-binding or excretion-promoting properties may be tested independently. Common candidate materials include pectin, algal polysaccharides, seaweed extracts, vitamins, trace elements such as calcium, zinc, and iron, traditional botanical preparations, and chelating agents of natural origin.

Sample Preparation Requirements

Test samples should be provided in sufficient quantity for both animal experiments and human trials, accompanied by a certificate of analysis, composition statement, recommended human dosage, and physical and chemical characterization. For animal dosing, samples are typically processed into homogeneous suspensions or solutions in an appropriate vehicle such as distilled water or carboxymethyl cellulose, and stability and contamination verification should confirm that the samples themselves are free from excessive lead background.

Testing Items

The Lead Excretion Promotion Function Test evaluates a comprehensive set of biological indicators covering lead burden, lead excretion, general health status, and trace element balance:

• Blood lead concentration — a biomarker of recent lead exposure and circulating lead burden.
• Bone lead content — the most stable and reliable indicator of long-term accumulated lead storage, measured in femur or other skeletal tissue.
• Liver and kidney lead content — indicators of lead distribution in metabolically active organs.
• Urinary lead excretion — quantitative measurement of lead eliminated through the renal pathway.
• Fecal lead excretion — quantitative measurement of lead eliminated through the hepatobiliary-intestinal pathway.
• Body weight and food intake — general health monitoring parameters throughout the dosing period.
• Hematological parameters — hemoglobin, red blood cell count, and related indices to detect lead-associated anemia.
• Essential trace elements — zinc, copper, calcium, iron, and magnesium levels to confirm that lead excretion does not cause loss of nutritional elements.
• Safety observations — organ coefficients, histopathological examination where required, and adverse event recording during human trials.

Testing Methods

Animal Experimental Design

The standard animal study uses healthy mice or rats of both sexes, randomly divided into groups including a blank control group, a lead-loaded model control group, a positive control group treated with a known lead-chelating agent such as dimercaptosuccinic acid, and three dose groups of the test substance corresponding to multiples of the recommended human intake, typically 5-fold, 10-fold, and 30-fold. A lead-burdened model is established by administering lead acetate in drinking water or by gavage over a defined induction period, and the test substance is administered concurrently or subsequently for 20 to 30 days. During the final collection phase, animals are placed in metabolic cages to collect 24-hour urine and feces specimens, followed by blood and tissue sampling at necropsy.

Analytical Techniques

Lead concentrations in biological matrices are determined using validated instrumental methods with appropriate sensitivity and quality control:

• Graphite furnace atomic absorption spectrometry (GFAAS) — the reference technique for blood lead and tissue lead quantification at trace levels.
• Inductively coupled plasma mass spectrometry (ICP-MS) — a high-sensitivity multi-element method used for simultaneous measurement of lead and essential trace elements in blood, urine, and digested tissue samples.
• Inductively coupled plasma optical emission spectrometry (ICP-OES) — suitable for samples with higher lead concentrations such as feces and digested bone.
• Acid digestion sample preparation — microwave-assisted or wet digestion of biological samples with nitric acid to release lead from the organic matrix prior to instrumental analysis.

Human Feeding Trial Design

The human trial enrolls adult subjects with elevated blood lead concentrations but without clinical lead poisoning symptoms. Participants are randomly assigned to a test group and a placebo control group in a double-blind design. The test product is consumed at the recommended daily dose for a period of typically 30 to 60 days, with monitoring of blood lead, urinary lead, essential trace element levels, routine blood and urine parameters, and liver and kidney function markers before and after the intervention. The trial must comply with ethical requirements and good clinical practice principles, with informed consent obtained from all participants.

Judgment Criteria

The functional claim is supported when predefined statistical criteria are met:

• In the animal test, the test groups show a statistically significant reduction in bone lead or blood lead compared with the lead-loaded model control group, or a significant increase in urinary or fecal lead excretion.
• The positive control group confirms model validity and assay sensitivity.
• In the human trial, the test group demonstrates a significant decrease in blood lead with a significant increase in urinary lead excretion compared with the placebo group.
• No significant reduction in essential trace elements and no clinically relevant adverse effects are observed in either animal or human studies.

Applications

The Lead Excretion Promotion Function Test serves multiple purposes across product development and regulatory compliance:

• Health food registration and filing — providing the functional evaluation dossier required for market authorization of products claiming a lead-excretion function.
• Functional claim substantiation — generating scientific evidence to support labeling claims and marketing statements.
• Product formulation optimization — comparing dose responses and ingredient combinations during research and development.
• Occupational health support products — evaluating products developed for populations with occupational lead exposure, such as battery manufacturing, smelting, painting, and recycling industries.
• Quality and efficacy research — supporting academic studies, patent applications, and publication of efficacy data.
• Import and export compliance — meeting documentation requirements for cross-border trade of functional food products.

FAQ

Q: What is the most reliable indicator of lead excretion efficacy?

A: Bone lead content is generally regarded as the most stable indicator because bone stores the majority of the body lead burden and reflects long-term accumulation. A significant reduction in bone lead, combined with increased urinary or fecal lead excretion, provides the strongest evidence of efficacy.

Q: Which animal species and model are used?

A: Mice or rats are used, and a lead-burdened model is established by administering lead acetate through drinking water or oral gavage. The model is validated by confirming significantly elevated blood and tissue lead levels in the model control group compared with the blank control group.

Q: How long does the complete evaluation take?

A: The animal experiment, including model establishment, dosing period, and sample analysis, typically requires several weeks of in-life work plus analytical time. The human feeding trial generally runs for 30 to 60 days of intervention in addition to recruitment, screening, and follow-up. The overall project duration depends on sample availability, protocol design, and reporting requirements.

Q: Why are essential trace elements measured during the test?

A: Lead excretion mechanisms, particularly chelation-based mechanisms, may inadvertently bind and eliminate essential minerals such as zinc, calcium, copper, and iron. Measuring these elements ensures that the product promotes lead excretion selectively without causing nutritional deficiency, which is a key safety criterion for functional approval.

Q: Can the test distinguish between reduced lead absorption and enhanced lead excretion?

A: Yes, the experimental design allows mechanistic interpretation. Reduced blood and tissue lead levels without increased urinary or fecal lead suggest inhibition of lead absorption, whereas reduced tissue lead accompanied by elevated urinary or fecal lead excretion confirms a genuine excretion-promoting function as required for the functional claim.

Q: Who should perform this test?

A: The evaluation should be conducted by accredited third-party laboratories or research institutions with validated analytical instrumentation, experience in health food function evaluation, appropriate laboratory animal facilities operating under good laboratory practice, and ethics committee approval for human trials.